Search

Your search keyword '"Tytgat, Godelieve A.M."' showing total 125 results
Start Over Author "Tytgat, Godelieve A.M."
125 results on '"Tytgat, Godelieve A.M."'

3. Integrative analysis of neuroblastoma by single-cell RNA sequencing identifies the NECTIN2-TIGIT axis as a target for immunotherapy

Author

Wienke, Judith, Visser, Lindy L., Kholosy, Waleed M., Keller, Kaylee M., Barisa, Marta, Poon, Evon, Munnings-Tomes, Sophie, Himsworth, Courtney, Calton, Elizabeth, Rodriguez, Ana, Bernardi, Ronald, van den Ham, Femke, van Hooff, Sander R., Matser, Yvette A.H., Tas, Michelle L., Langenberg, Karin P.S., Lijnzaad, Philip, Borst, Anne L., Zappa, Elisa, Bergsma, Francisca J., Strijker, Josephine G.M., Verhoeven, Bronte M., Mei, Shenglin, Kramdi, Amira, Restuadi, Restuadi, Sanchez-Bernabeu, Alvaro, Cornel, Annelisa M., Holstege, Frank C.P., Gray, Juliet C., Tytgat, Godelieve A.M., Scheijde-Vermeulen, Marijn A., Wijnen, Marc H.W.A., Dierselhuis, Miranda P., Straathof, Karin, Behjati, Sam, Wu, Wei, Heck, Albert J.R., Koster, Jan, Nierkens, Stefan, Janoueix-Lerosey, Isabelle, de Krijger, Ronald R., Baryawno, Ninib, Chesler, Louis, Anderson, John, Caron, Hubert N., Margaritis, Thanasis, van Noesel, Max M., and Molenaar, Jan J.

Published
2024
Full Text
View/download PDF

4. Cell-Free DNA as a Diagnostic and Prognostic Biomarker in Pediatric Rhabdomyosarcoma

Author

Lak, Nathalie S.M., van Zogchel, Lieke M.J., Zappeij-Kannegieter, Lily, Javadi, Ahmad, van Paemel, Ruben, Vandeputte, Charlotte, De Preter, Katleen, De Wilde, Bram, Chicard, Mathieu, Iddir, Yasmine, Schleiermacher, Gudrun, Ruhen, Olivia, Shipley, Janet, Fiocco, Marta, Merks, Johannes H.M., van Noesel, Max M., van der Schoot, C. Ellen, Tytgat, Godelieve A.M., and Stutterheim, Janine

Published
2023
Full Text
View/download PDF

5. A narrative review of 35 years of meta-[131I]iodobenzylguanidine therapy in neuroblastoma

Author

Researchgr. Nucleaire Geneeskunde, Cancer, Onderzoek Beeld, MS Radiologie, Samim, Atia, Bleeker, Gitta, Kraal, Kathelijne C.J.M., van Noesel, Max M., de Keizer, Bart, Tytgat, Godelieve A.M., Researchgr. Nucleaire Geneeskunde, Cancer, Onderzoek Beeld, MS Radiologie, Samim, Atia, Bleeker, Gitta, Kraal, Kathelijne C.J.M., van Noesel, Max M., de Keizer, Bart, and Tytgat, Godelieve A.M.

Published
2024

8. Supplemental Figures 1 and 2 from Peripheral Stem Cell Apheresis is Feasible Post 131Iodine-Metaiodobenzylguanidine-Therapy in High-Risk Neuroblastoma, but Results in Delayed Platelet Reconstitution

Author

Kraal, Kathelijne C.J.M., primary, Timmerman, Ilse, primary, Kansen, Hannah M., primary, van den Bos, Cor, primary, Zsiros, Jozsef, primary, van den Berg, Henk, primary, Somers, Sebastiaan, primary, Braakman, Eric, primary, Peek, Annemarie M.L., primary, van Noesel, Max M., primary, van der Schoot, C. Ellen, primary, Fiocco, Marta, primary, Caron, Huib N., primary, Voermans, Carlijn, primary, and Tytgat, Godelieve A.M., primary

Published
2023
Full Text
View/download PDF

11. Legends from Peripheral Stem Cell Apheresis is Feasible Post 131Iodine-Metaiodobenzylguanidine-Therapy in High-Risk Neuroblastoma, but Results in Delayed Platelet Reconstitution

Author

Kraal, Kathelijne C.J.M., primary, Timmerman, Ilse, primary, Kansen, Hannah M., primary, van den Bos, Cor, primary, Zsiros, Jozsef, primary, van den Berg, Henk, primary, Somers, Sebastiaan, primary, Braakman, Eric, primary, Peek, Annemarie M.L., primary, van Noesel, Max M., primary, van der Schoot, C. Ellen, primary, Fiocco, Marta, primary, Caron, Huib N., primary, Voermans, Carlijn, primary, and Tytgat, Godelieve A.M., primary

Published
2023
Full Text
View/download PDF

13. Supplemental Table 1 and 2 from Peripheral Stem Cell Apheresis is Feasible Post 131Iodine-Metaiodobenzylguanidine-Therapy in High-Risk Neuroblastoma, but Results in Delayed Platelet Reconstitution

Author

Kraal, Kathelijne C.J.M., primary, Timmerman, Ilse, primary, Kansen, Hannah M., primary, van den Bos, Cor, primary, Zsiros, Jozsef, primary, van den Berg, Henk, primary, Somers, Sebastiaan, primary, Braakman, Eric, primary, Peek, Annemarie M.L., primary, van Noesel, Max M., primary, van der Schoot, C. Ellen, primary, Fiocco, Marta, primary, Caron, Huib N., primary, Voermans, Carlijn, primary, and Tytgat, Godelieve A.M., primary

Published
2023
Full Text
View/download PDF

17. Targeted locus amplification to develop robust patient-specific assays for liquid biopsies in pediatric solid tumors

Author

Afd Pharmaceutics, Pharmaceutics, van Zogchel, Lieke M.J., Lak, Nathalie S.M., Gelineau, Nina U., Sergeeva, Irina, Stelloo, Ellen, Swennenhuis, Joost, Feitsma, Harma, van Min, Max, Splinter, Erik, Bleijs, Margit, Groot Koerkamp, Marian, Breunis, Willemijn, Meister, Michael Torsten, Kholossy, Waleed Hassan, Holstege, Frank C.P., Molenaar, Jan J., de Leng, Wendy W.J., Stutterheim, Janine, van der Schoot, C. Ellen, Tytgat, Godelieve A.M., Afd Pharmaceutics, Pharmaceutics, van Zogchel, Lieke M.J., Lak, Nathalie S.M., Gelineau, Nina U., Sergeeva, Irina, Stelloo, Ellen, Swennenhuis, Joost, Feitsma, Harma, van Min, Max, Splinter, Erik, Bleijs, Margit, Groot Koerkamp, Marian, Breunis, Willemijn, Meister, Michael Torsten, Kholossy, Waleed Hassan, Holstege, Frank C.P., Molenaar, Jan J., de Leng, Wendy W.J., Stutterheim, Janine, van der Schoot, C. Ellen, and Tytgat, Godelieve A.M.

Published
2023

18. MEK inhibition causes BIM stabilization and increased sensitivity to BCL-2 family member inhibitors in RAS-MAPK-mutated neuroblastoma

Author

Sub General Pharmaceutics, Afd Pharmaceutics, Pharmaceutics, Eleveld, Thomas F., Vernooij, Lindy, Schild, Linda, Koopmans, Bianca, Alles, Lindy K., Ebus, Marli E., Dandis, Rana, van Tinteren, Harm, Caron, Huib N., Koster, Jan, van Noesel, Max M., Tytgat, Godelieve A.M., Eising, Selma, Versteeg, Rogier, Dolman, M. Emmy M., Molenaar, Jan J., Sub General Pharmaceutics, Afd Pharmaceutics, Pharmaceutics, Eleveld, Thomas F., Vernooij, Lindy, Schild, Linda, Koopmans, Bianca, Alles, Lindy K., Ebus, Marli E., Dandis, Rana, van Tinteren, Harm, Caron, Huib N., Koster, Jan, van Noesel, Max M., Tytgat, Godelieve A.M., Eising, Selma, Versteeg, Rogier, Dolman, M. Emmy M., and Molenaar, Jan J.

Published
2023

19. [18F]mFBG PET-CT for detection and localisation of neuroblastoma: a prospective pilot study

Author

Radionuclide Apotheek, Cancer, MS Radiologie, Fysica Radiologie, Onderzoek Beeld, Researchgr. Nucleaire Geneeskunde, Samim, Atia, Blom, Thomas, Poot, Alex J., Windhorst, Albert D., Fiocco, Marta, Tolboom, Nelleke, Braat, Arthur J.A.T., Viol, Sebastiaan L.Meyer, van Rooij, Rob, van Noesel, Max M., Lam, Marnix G.E.H., Tytgat, Godelieve A.M., de Keizer, Bart, Radionuclide Apotheek, Cancer, MS Radiologie, Fysica Radiologie, Onderzoek Beeld, Researchgr. Nucleaire Geneeskunde, Samim, Atia, Blom, Thomas, Poot, Alex J., Windhorst, Albert D., Fiocco, Marta, Tolboom, Nelleke, Braat, Arthur J.A.T., Viol, Sebastiaan L.Meyer, van Rooij, Rob, van Noesel, Max M., Lam, Marnix G.E.H., Tytgat, Godelieve A.M., and de Keizer, Bart

Published
2023

20. Pharmacological protection of the thyroid gland against radiation damage from radioactive iodine labeled compounds in children: a systematic review

Author

Apotheek Klinische Farmacie, MS Radiologie, Cancer, Endocrinologie patientenzorg, Brain, Child Health, de Lijster, Bas, de Kanter, Clara T.M.M., de Keizer, Bart, Tytgat, Godelieve A.M., Vulsma, Thomas, Offringa, Martin, van Santen, Hanneke M., Apotheek Klinische Farmacie, MS Radiologie, Cancer, Endocrinologie patientenzorg, Brain, Child Health, de Lijster, Bas, de Kanter, Clara T.M.M., de Keizer, Bart, Tytgat, Godelieve A.M., Vulsma, Thomas, Offringa, Martin, and van Santen, Hanneke M.

Published
2023

21. Optimising urinary catecholamine metabolite diagnostics for neuroblastoma

Author

Gray, Juliet, Matser, Yvette A.H., Verly, Iedan R.N., van der Ham, Maria, de Sain-van der Velden, Monique G.M., Verhoeven-Duif, Nanda M., Ash, Shifra, Cangemi, Giuliana, Barco, Sebastiano, Popovic, Maja Beck, van Kuilenburg, Andre B.P., and Tytgat, Godelieve A.M.

Abstract

IntroductionThe analysis of urinary catecholamine metabolites is a cornerstone of neuroblastoma diagnostics. Currently, there is no consensus regarding the sampling method, and variable combinations of catecholamine metabolites are being used. We investigated if spot urine samples can be reliably used for analysis of a panel of catecholamine metabolites for the diagnosis of neuroblastoma.MethodsTwenty-four-hour urine or spot urine samples were collected from patients with and without neuroblastoma at diagnosis. Homovanillic acid (HVA), vanillylmandelic acid (VMA), dopamine, 3-methoxytyramine, norepinephrine, normetanephrine, epinephrine and metanephrine were measured by high-performance liquid chromatography coupled with fluorescence detection (HPLC-FD) and/or ultra-performance liquid chromatography coupled with electrospray tandem mass spectrometry (UPLC-MS/MS).ResultsCatecholamine metabolite levels were measured in urine samples of 400 neuroblastoma patients (24-hour urine, n = 234; spot urine, n = 166) and 571 controls (all spot urine). Excretion levels of catecholamine metabolites and the diagnostic sensitivity for each metabolite were similar in 24-hour urine and spot urine samples (p > .08 and >.27 for all metabolites). The area under the receiver-operating-characteristic curve (AUC) of the panel containing all eight catecholamine metabolites was significantly higher compared to that of only HVA and VMA (AUC = 0.952 vs. 0.920, p = .02). No differences were observed in metabolite levels between the two analysis methods.ConclusionCatecholamine metabolites in spot urine and 24-hour urine resulted in similar diagnostic sensitivities. The Catecholamine Working Group recommends the implementation of spot urine as standard of care. The panel of eight catecholamine metabolites has superior diagnostic accuracy over VMA and HVA.

Published
2023

23. Chromosome 11q loss and MYCN amplification demonstrate synthetic lethality with checkpoint kinase 1 inhibition in neuroblastoma

Author

Keller, Kaylee M., Eleveld, Thomas F., Schild, Linda, van den Handel, Kim, van den Boogaard, Marlinde, Amo-Addae, Vicky, Eising, Selma, Ober, Kimberley, Koopmans, Bianca, Looijenga, Leendert, Tytgat, Godelieve A.M., Ylstra, Bauke, Molenaar, Jan J., Dolman, M. Emmy M., van Hooff, Sander R., Afd Pharmaceutics, Pharmaceutics, Afd Pharmaceutics, Pharmaceutics, Pathology, CCA - Cancer biology and immunology, Paediatric Oncology, and Center of Experimental and Molecular Medicine

Subjects
neuroblastoma, Cancer Research, Oncology, MYCN amplification, prexasertib, replication stress, chromosome 11q deletion, synergy, checkpoint kinase 1 (CHK1), pediatric cancer
Abstract

Neuroblastoma is the most common extracranial solid tumor found in children and despite intense multi-modal therapeutic approaches, low overall survival rates of high-risk patients persist. Tumors with heterozygous loss of chromosome 11q and MYCN amplification are two genetically distinct subsets of neuroblastoma that are associated with poor patient outcome. Using an isogenic 11q deleted model system and high-throughput drug screening, we identify checkpoint kinase 1 (CHK1) as a potential therapeutic target for 11q deleted neuroblastoma. Further investigation reveals MYCN amplification as a possible additional biomarker for CHK1 inhibition, independent of 11q loss. Overall, our study highlights the potential power of studying chromosomal aberrations to guide preclinical development of novel drug targets and combinations. Additionally, our study builds on the growing evidence that DNA damage repair and replication stress response pathways offer therapeutic vulnerabilities for the treatment of neuroblastoma.

Published
2022

25. Molecular Characterization of Circulating Tumor DNA in Pediatric Rhabdomyosarcoma: A Feasibility Study

Author

Ruhen, Olivia, primary, Lak, Nathalie S.M., additional, Stutterheim, Janine, additional, Danielli, Sara G., additional, Chicard, Mathieu, additional, Iddir, Yasmine, additional, Saint-Charles, Alexandra, additional, Di Paolo, Virginia, additional, Tombolan, Lucia, additional, Gatz, Susanne A., additional, Aladowicz, Ewa, additional, Proszek, Paula, additional, Jamal, Sabri, additional, Stankunaite, Reda, additional, Hughes, Deborah, additional, Carter, Paul, additional, Izquierdo, Elisa, additional, Wasti, Ajla, additional, Chisholm, Julia C., additional, George, Sally L., additional, Pace, Erika, additional, Chesler, Louis, additional, Aerts, Isabelle, additional, Pierron, Gaelle, additional, Zaidi, Sakina, additional, Delattre, Olivier, additional, Surdez, Didier, additional, Kelsey, Anna, additional, Hubank, Michael, additional, Bonvini, Paolo, additional, Bisogno, Gianni, additional, Di Giannatale, Angela, additional, Schleiermacher, Gudrun, additional, Schäfer, Beat W., additional, Tytgat, Godelieve A.M., additional, and Shipley, Janet, additional

Published
2022
Full Text
View/download PDF

26. Mutational spectrum of ATRX aberrations in neuroblastoma and associated patient and tumor characteristics

Author

van Gerven, Michael R., Bozsaky, Eva, Matser, Yvette A.H., Vosseberg, Julian, Taschner-Mandl, Sabine, Koster, Jan, Tytgat, Godelieve A.M., Molenaar, Jan J., van den Boogaard, Marlinde, Sub Bioinformatics, Afd Pharmaceutics, Theoretical Biology and Bioinformatics, Pharmaceutics, Laboratory Genetic Metabolic Diseases, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, Center of Experimental and Molecular Medicine, Oncogenomics, CCA - Cancer biology and immunology, Paediatric Oncology, Sub Bioinformatics, Afd Pharmaceutics, Theoretical Biology and Bioinformatics, and Pharmaceutics

Subjects
X-linked Nuclear Protein, Cancer Research, ALT, DNA Helicases, 11q deletion, General Medicine, pediatric oncology, Chromatin, neuroblastoma, Phenotype, ATRX, Oncology, Mutation, Humans
Abstract

Neuroblastoma is the most common extracranial solid tumor in children. The chromatin remodeler ATRX is frequently mutated in high-risk patients with a poor prognosis. Although many studies have reported ATRX aberrations and the associated clinical characteristics in neuroblastoma, a comprehensive overview is currently lacking. In this study, we extensively characterize the mutational spectrum of ATRX aberrations in neuroblastoma tumors reported in previous studies and present an overview of patient and tumor characteristics. We collected the data of a total of 127 neuroblastoma patients and three cell lines with ATRX aberrations originating from 20 papers. We subdivide the ATRX aberrations into nonsense, missense, and multiexon deletions (MEDs) and show that 68% of them are MEDs. Of these MEDs, 75% are predicted to be in-frame. Furthermore, we identify a missense mutational hotspot region in the helicase domain. We also confirm that all three ATRX mutation types are more often identified in patients diagnosed at an older age, but still approximately 40% of the patients are aged 5 years or younger at diagnosis. Surprisingly, we found that 11q deletions are enriched in neuroblastomas with ATRX deletions compared to a reference cohort, but not in neuroblastomas with ATRX point mutations. Taken together, our data emphasizes a distinct ATRX mutation spectrum in neuroblastoma, which should be considered when studying molecular phenotypes and therapeutic strategies.

Published
2022

27. Mutational spectrum of ATRX aberrations in neuroblastoma and associated patient and tumor characteristics

Author

Sub Bioinformatics, Afd Pharmaceutics, Theoretical Biology and Bioinformatics, Pharmaceutics, van Gerven, Michael R., Bozsaky, Eva, Matser, Yvette A.H., Vosseberg, Julian, Taschner-Mandl, Sabine, Koster, Jan, Tytgat, Godelieve A.M., Molenaar, Jan J., van den Boogaard, Marlinde, Sub Bioinformatics, Afd Pharmaceutics, Theoretical Biology and Bioinformatics, Pharmaceutics, van Gerven, Michael R., Bozsaky, Eva, Matser, Yvette A.H., Vosseberg, Julian, Taschner-Mandl, Sabine, Koster, Jan, Tytgat, Godelieve A.M., Molenaar, Jan J., and van den Boogaard, Marlinde

Published
2022

28. Chromosome 11q loss and MYCN amplification demonstrate synthetic lethality with checkpoint kinase 1 inhibition in neuroblastoma

Author

Afd Pharmaceutics, Pharmaceutics, Keller, Kaylee M., Eleveld, Thomas F., Schild, Linda, van den Handel, Kim, van den Boogaard, Marlinde, Amo-Addae, Vicky, Eising, Selma, Ober, Kimberley, Koopmans, Bianca, Looijenga, Leendert, Tytgat, Godelieve A.M., Ylstra, Bauke, Molenaar, Jan J., Dolman, M. Emmy M., van Hooff, Sander R., Afd Pharmaceutics, Pharmaceutics, Keller, Kaylee M., Eleveld, Thomas F., Schild, Linda, van den Handel, Kim, van den Boogaard, Marlinde, Amo-Addae, Vicky, Eising, Selma, Ober, Kimberley, Koopmans, Bianca, Looijenga, Leendert, Tytgat, Godelieve A.M., Ylstra, Bauke, Molenaar, Jan J., Dolman, M. Emmy M., and van Hooff, Sander R.

Published
2022

29. Refractory Stage M Ganglioneuroblastoma with Bone Metastases and a Favorable, Chronic Course of Disease:Description of a Patient Cohort

Author

Tas, Michelle L., Molenaar, Jan J., Peek, Annemarie M.L., Lequin, Maarten H., Verdijk, Rob M., de Krijger, Ronald R., Tytgat, Godelieve A.M., van Noesel, Max M., Tas, Michelle L., Molenaar, Jan J., Peek, Annemarie M.L., Lequin, Maarten H., Verdijk, Rob M., de Krijger, Ronald R., Tytgat, Godelieve A.M., and van Noesel, Max M.

Abstract

Refractory stage M neuroblastoma (NB) is associated with a poor prognosis and a progressive course of disease. Here, we describe a unique group of patients with a discrepant clinical course. Seven histologically confirmed ganglioneuroblastoma (GNB) (n = 6) and differentiating NB (n = 1) patients were identified who were diagnosed with stage M disease based on iodine-123-metaiodobenzylguanidine avid bone metastases. Six patients started on high-risk treatment, without tumor response (stable disease). Treatment was discontinued before the start of consolidation treatment because of refractory response in all patients. Unexpectedly, after cessation of treatment no progression of disease occurred. In 2 patients, the primary tumors expanded (> 25%) very slowly during 1.5 and 3 years, and remained stable thereafter. Metabolically, a slow decrease of urinary homovanillic acid and vanillylmandelic acid levels and iodine-123-metaiodobenzylguanidine avidity was observed. All patients are alive with presence of metastatic disease after a median follow-up of 17 years (range: 6.7 to 27 y). Interestingly, at diagnosis, 6 patients were asymptomatic, 6 patients had GNB morphology, and 5 patients had meningeal metastases. These are all features seen in only a small minority of stage M patients. This GNB entity illustrates the clinical heterogeneity of neuroblastic tumors and can be used to further study the developmental origin of different NB subtypes.

Published
2022

30. Characteristics and Outcome of Children with Wilms Tumor Requiring Intensive Care Admission in First Line Therapy

Author

Arts-assistenten Kinderen, Intensieve zorg, Zorgeenheid Kinderchirurgie Medisch, Nefrologie, Child Health, Pathologie Pathologen staf, MS Radiologie, Cancer, MS Radiotherapie, PMC Medisch specialisten, Speerpunt, Zorg en O&O, Intensive care patientenzorg, Steur, Anouk, Raymakers-Janssen, Paulien A.M.A., Kneyber, Martin C.J., Dijkstra, Sandra, van Woensel, Job B.M., van Waardenburg, Dick A., van de Ven, Cornelis P., van der Steeg, Alida F.W., Wijnen, Marc, Lilien, Marc R., de Krijger, Ronald R., van Tinteren, Harm, Littooij, Annemieke S., Janssens, Geert O., Peek, Annemarie M.L., Tytgat, Godelieve A.M., Mavinkurve-Groothuis, Annelies M., van Grotel, Martine, van den Heuvel-Eibrink, Marry M., Wösten-Van Asperen, Roelie M., Arts-assistenten Kinderen, Intensieve zorg, Zorgeenheid Kinderchirurgie Medisch, Nefrologie, Child Health, Pathologie Pathologen staf, MS Radiologie, Cancer, MS Radiotherapie, PMC Medisch specialisten, Speerpunt, Zorg en O&O, Intensive care patientenzorg, Steur, Anouk, Raymakers-Janssen, Paulien A.M.A., Kneyber, Martin C.J., Dijkstra, Sandra, van Woensel, Job B.M., van Waardenburg, Dick A., van de Ven, Cornelis P., van der Steeg, Alida F.W., Wijnen, Marc, Lilien, Marc R., de Krijger, Ronald R., van Tinteren, Harm, Littooij, Annemieke S., Janssens, Geert O., Peek, Annemarie M.L., Tytgat, Godelieve A.M., Mavinkurve-Groothuis, Annelies M., van Grotel, Martine, van den Heuvel-Eibrink, Marry M., and Wösten-Van Asperen, Roelie M.

Published
2022

34. Organoid-based drug screening reveals neddylation as therapeutic target for malignant rhabdoid tumors

Author

Calandrini, Camilla, primary, van Hooff, Sander R., additional, Paassen, Irene, additional, Ayyildiz, Dilara, additional, Derakhshan, Sepide, additional, Dolman, M. Emmy M., additional, Langenberg, Karin P.S., additional, van de Ven, Marieke, additional, de Heus, Cecilia, additional, Liv, Nalan, additional, Kool, Marcel, additional, de Krijger, Ronald R., additional, Tytgat, Godelieve A.M., additional, van den Heuvel-Eibrink, Marry M., additional, Molenaar, Jan J., additional, and Drost, Jarno, additional

Published
2021
Full Text
View/download PDF

35. Improving Risk Stratification for Pediatric Patients with Rhabdomyosarcoma by Molecular Detection of Disseminated Disease

Author

Lak, Nathalie S.M., primary, Voormanns, Timon L., additional, Zappeij-Kannegieter, Lily, additional, van Zogchel, Lieke M.J., additional, Fiocco, Marta, additional, van Noesel, Max M., additional, Merks, Johannes H.M., additional, van der Schoot, C. Ellen, additional, Tytgat, Godelieve A.M., additional, and Stutterheim, Janine, additional

Published
2021
Full Text
View/download PDF

36. Locoregional control using highly conformal flank target volumes and volumetric-modulated arc therapy in pediatric renal tumors: Results from the Dutch national cohort

Author

Mul, Joeri, primary, van Grotel, Martine, additional, Seravalli, Enrica, additional, Bosman, Mirjam E., additional, van Tinteren, Harm, additional, Roy, Prakriti, additional, Dávila Fajardo, Raquel, additional, Tytgat, Godelieve A.M., additional, Mavinkurve-Groothuis, Annelies M.C., additional, van de Ven, Cornelis P., additional, Wijnen, Marc H.W.A., additional, de Krijger, Ronald R., additional, Littooij, Annemieke S., additional, van den Heuvel-Eibrink, Marry M., additional, and Janssens, Geert O., additional

Published
2021
Full Text
View/download PDF

37. Combining hypermethylated rassf1a detection using ddpcr with mir-371a-3p testing:An improved panel of liquid biopsy biomarkers for testicular germ cell tumor patients

Author

Lobo, João, van Zogchel, Lieke M.J., Nuru, Mohammed G., Gillis, Ad J.M., van der Schoot, C. Ellen, Tytgat, Godelieve A.M., Looijenga, Leendert H.J., Lobo, João, van Zogchel, Lieke M.J., Nuru, Mohammed G., Gillis, Ad J.M., van der Schoot, C. Ellen, Tytgat, Godelieve A.M., and Looijenga, Leendert H.J.

Abstract

The classical serum tumor markers used routinely in the management of testicular germ cell tumor (TGCT) patients—alpha fetoprotein (AFP) and human chorionic gonadotropin (HCG)— show important limitations. miR-371a-3p is the most recent promising biomarker for TGCTs, but it is not sufficiently informative for detection of teratoma, which is therapeutically relevant. We aimed to test the feasibility of hypermethylated RASSF1A (RASSF1AM) detected in circulating cell-free DNA as a non-invasive diagnostic marker of testicular germ cell tumors, combined with miR-371a-3p. A total of 109 serum samples of patients and 29 sera of healthy young adult males were included, along with representative cell lines and tumor tissue samples. We describe a novel droplet digital polymerase chain reaction (ddPCR) method for quantitatively assessing RASSF1AM in liquid biopsies. Both miR-371a-3p (sensitivity = 85.7%) and RASSF1AM (sensitivity = 86.7%) outperformed the combination of AFP and HCG (sensitivity = 65.5%) for TGCT diagnosis. RASSF1AM detected 88% of teratomas. In this representative cohort, 14 cases were negative for miR-371a-3p, all of which were detected by RASSF1AM, resulting in a combined sensitivity of 100%. We have described a highly sensitive and specific panel of biomarkers for TGCT patients, to be validated in the context of patient follow-up and detection of minimal residual disease.

Published
2021

38. Anti-GD2 based immunotherapy prevents late events in high-risk neuroblastoma patients over 18 months at diagnosis

Author

Tas, Michelle L., Dootjes, Lisa W., Fiocco, Marta, de Krijger, Ronald R., Dierselhuis, Miranda P., van Eijkelenburg, Natasha K.A., van Grotel, Martine, Kraal, Kathelijne C.J.M., Peek, Annemarie M.L., Tytgat, Godelieve A.M., van Noesel, Max M., Tas, Michelle L., Dootjes, Lisa W., Fiocco, Marta, de Krijger, Ronald R., Dierselhuis, Miranda P., van Eijkelenburg, Natasha K.A., van Grotel, Martine, Kraal, Kathelijne C.J.M., Peek, Annemarie M.L., Tytgat, Godelieve A.M., and van Noesel, Max M.

Abstract

Background: Anti-GD2 based immunotherapy has improved overall (OS) and event free survival (EFS) for high-risk neuroblastoma (HR-NBL) patients. Here, we evaluate the long-term efficacy of anti-GD2 immunotherapy in combination with isotretinoin, GM-CSF, and IL-2. Methods: Dutch HR-NBL patients treated with immunotherapy according to the COG-ANBL0032 protocol (n = 47) were included and compared to historical controls (n = 37) treated with single-agent isotret-inoin maintenance therapy. Survival time was calculated from start of the maintenance therapy. Results: The study and control group were similar concerning baseline characteristics. In the com-plete cohort, 5 year OS was 64±7% and 49±8% for the immunotherapy group and the control group, respectively (p = 0.16). Five year EFS was 57±7% and 41±8%, respectively (p = 0.16). In the subgroup of patients ≥ 18 months, 5-yr OS was 63±8% and 39±9, respectively (p = 0.04) and EFS 54±8% and 29±8%, respectively (p = 0.05). Landmark analysis for EFS with landmark point at 6 months after start of maintenance suggests a larger effect on the prevention of late than early events. Conclusions: This study is the first to confirm the results of the COG-ANBL0032 study in a cohort treated with a different induction regimen. Anti-GD2 immunotherapy prevents late events, most significantly in patients older than 18 months of age at diagnosis.

Published
2021

39. Anti-GD2 based immunotherapy prevents late events in high-risk neuroblastoma patients over 18 months at diagnosis

Author

Pathologie Pathologen staf, Arts-assistenten Kinderen, PMC Medisch specialisten, Onderzoek Beeld, Tas, Michelle L., Dootjes, Lisa W., Fiocco, Marta, de Krijger, Ronald R., Dierselhuis, Miranda P., van Eijkelenburg, Natasha K.A., van Grotel, Martine, Kraal, Kathelijne C.J.M., Peek, Annemarie M.L., Tytgat, Godelieve A.M., van Noesel, Max M., Pathologie Pathologen staf, Arts-assistenten Kinderen, PMC Medisch specialisten, Onderzoek Beeld, Tas, Michelle L., Dootjes, Lisa W., Fiocco, Marta, de Krijger, Ronald R., Dierselhuis, Miranda P., van Eijkelenburg, Natasha K.A., van Grotel, Martine, Kraal, Kathelijne C.J.M., Peek, Annemarie M.L., Tytgat, Godelieve A.M., and van Noesel, Max M.

Published
2021

40. Organoid-based drug screening reveals neddylation as therapeutic target for malignant rhabdoid tumors

Author

Groep Holstege, CMM Groep Klumperman, Cancer, CMM Sectie Celbiologie, CMM groep Liv, Pathologie Pathologen staf, Speerpunt, Zorg en O&O, Child Health, Calandrini, Camilla, van Hooff, Sander R., Paassen, Irene, Ayyildiz, Dilara, Derakhshan, Sepide, Dolman, M. Emmy M., Langenberg, Karin P.S., van de Ven, Marieke, de Heus, Cecilia, Liv, Nalan, Kool, Marcel, de Krijger, Ronald R., Tytgat, Godelieve A.M., van den Heuvel-Eibrink, Marry M., Molenaar, Jan J., Drost, Jarno, Groep Holstege, CMM Groep Klumperman, Cancer, CMM Sectie Celbiologie, CMM groep Liv, Pathologie Pathologen staf, Speerpunt, Zorg en O&O, Child Health, Calandrini, Camilla, van Hooff, Sander R., Paassen, Irene, Ayyildiz, Dilara, Derakhshan, Sepide, Dolman, M. Emmy M., Langenberg, Karin P.S., van de Ven, Marieke, de Heus, Cecilia, Liv, Nalan, Kool, Marcel, de Krijger, Ronald R., Tytgat, Godelieve A.M., van den Heuvel-Eibrink, Marry M., Molenaar, Jan J., and Drost, Jarno

Published
2021

41. Bilateral Renal Tumors in Children: The First 5 Years' Experience of National Centralization in The Netherlands and a Narrative Review of the Literature

Author

Genetica Klinische Genetica, PMC Medisch specialisten, MS Radiotherapie, MS Radiologie, Cancer, Pathologie Pathologen staf, Genetica, Child Health, Nefrologie, Zorgeenheid Kinderchirurgie Medisch, Speerpunt, Zorg en O&O, van Peer, Sophie E., Hol, Janna A., van der Steeg, Alida F.W., van Grotel, Martine, Tytgat, Godelieve A.M., Mavinkurve‐groothuis, Annelies M.C., Janssens, Geert O.R., Littooij, Annemieke S., de Krijger, Ronald R., Jongmans, Marjolijn C.J., Lilien, Marc R., Drost, Jarno, Kuiper, Roland P., van Tinteren, Harm, Wijnen, Marc H.W.A., van den Heuvel‐Eibrink, Marry M., Genetica Klinische Genetica, PMC Medisch specialisten, MS Radiotherapie, MS Radiologie, Cancer, Pathologie Pathologen staf, Genetica, Child Health, Nefrologie, Zorgeenheid Kinderchirurgie Medisch, Speerpunt, Zorg en O&O, van Peer, Sophie E., Hol, Janna A., van der Steeg, Alida F.W., van Grotel, Martine, Tytgat, Godelieve A.M., Mavinkurve‐groothuis, Annelies M.C., Janssens, Geert O.R., Littooij, Annemieke S., de Krijger, Ronald R., Jongmans, Marjolijn C.J., Lilien, Marc R., Drost, Jarno, Kuiper, Roland P., van Tinteren, Harm, Wijnen, Marc H.W.A., and van den Heuvel‐Eibrink, Marry M.

Published
2021

42. Locoregional control using highly conformal flank target volumes and volumetric-modulated arc therapy in pediatric renal tumors: Results from the Dutch national cohort

Author

PMC Medisch specialisten, Klinische Fysica RT, Cancer, MS Radiotherapie, NEMI, Zorgeenheid Kinderchirurgie Medisch, Pathologie Pathologen staf, MS Radiologie, Speerpunt, Zorg en O&O, Child Health, Mul, Joeri, van Grotel, Martine, Seravalli, Enrica, Bosman, Mirjam E., van Tinteren, Harm, Roy, Prakriti, Dávila Fajardo, Raquel, Tytgat, Godelieve A.M., Mavinkurve-Groothuis, Annelies M.C., van de Ven, Cornelis P., Wijnen, Marc H.W.A., de Krijger, Ronald R., Littooij, Annemieke S., van den Heuvel-Eibrink, Marry M., Janssens, Geert O., PMC Medisch specialisten, Klinische Fysica RT, Cancer, MS Radiotherapie, NEMI, Zorgeenheid Kinderchirurgie Medisch, Pathologie Pathologen staf, MS Radiologie, Speerpunt, Zorg en O&O, Child Health, Mul, Joeri, van Grotel, Martine, Seravalli, Enrica, Bosman, Mirjam E., van Tinteren, Harm, Roy, Prakriti, Dávila Fajardo, Raquel, Tytgat, Godelieve A.M., Mavinkurve-Groothuis, Annelies M.C., van de Ven, Cornelis P., Wijnen, Marc H.W.A., de Krijger, Ronald R., Littooij, Annemieke S., van den Heuvel-Eibrink, Marry M., and Janssens, Geert O.

Published
2021

45. Neuroblastoma stage 4S: Tumor regression rate and risk factors of progressive disease

Author

MS Radiologie, Cancer, Tas, Michelle L., Nagtegaal, Michelle, Kraal, Kathelijne C.J.M., Tytgat, Godelieve A.M., Abeling, Nico G.G.M., Koster, Jan, Pluijm, Saskia M.F., Zwaan, C. Michel, de Keizer, Bart, Molenaar, Jan J., van Noesel, Max M., MS Radiologie, Cancer, Tas, Michelle L., Nagtegaal, Michelle, Kraal, Kathelijne C.J.M., Tytgat, Godelieve A.M., Abeling, Nico G.G.M., Koster, Jan, Pluijm, Saskia M.F., Zwaan, C. Michel, de Keizer, Bart, Molenaar, Jan J., and van Noesel, Max M.

Published
2020

46. Characteristics and outcome of children with renal cell carcinoma: A narrative review

Author

Onderzoek Beeld, Cancer, Pathologie Patiëntenadministratie, Pathologie Pathologen staf, MS Radiologie, Speerpunt, Zorg en O&O, Child Health, van der Beek, Justine N., Geller, James I., de Krijger, Ronald R., Graf, Norbert, Pritchard-Jones, Kathy, Drost, Jarno, Verschuur, Arnauld C., Murphy, Dermot, Ray, Satyajit, Spreafico, Filippo, Dzhuma, Kristina, Littooij, Annemieke S., Selle, Barbara, Tytgat, Godelieve A.M., van den Heuvel-Eibrink, Marry M., Onderzoek Beeld, Cancer, Pathologie Patiëntenadministratie, Pathologie Pathologen staf, MS Radiologie, Speerpunt, Zorg en O&O, Child Health, van der Beek, Justine N., Geller, James I., de Krijger, Ronald R., Graf, Norbert, Pritchard-Jones, Kathy, Drost, Jarno, Verschuur, Arnauld C., Murphy, Dermot, Ray, Satyajit, Spreafico, Filippo, Dzhuma, Kristina, Littooij, Annemieke S., Selle, Barbara, Tytgat, Godelieve A.M., and van den Heuvel-Eibrink, Marry M.

Published
2020

47. An organoid biobank for childhood kidney cancers that captures disease and tissue heterogeneity

Author

Nefro Vasculaire Geneeskunde, Groep Holstege, CMM Groep Klumperman, MS Nefrologie, Regenerative Medicine and Stem Cells, Circulatory Health, Pathologie Groep Blokx, Pathologie Pathologen staf, Child Health, CMM Groep Cuppen, Cancer, CMM Sectie Molecular Cancer Research, Hubrecht Institute with UMC, Calandrini, Camilla, Schutgens, Frans, Oka, Rurika, Margaritis, Thanasis, Candelli, Tito, Mathijsen, Luka, Ammerlaan, Carola, van Ineveld, Ravian L., Derakhshan, Sepide, de Haan, Sanne, Dolman, Emmy, Lijnzaad, Philip, Custers, Lars, Begthel, Harry, Kerstens, Hindrik H.D., Visser, Lindy L., Rookmaaker, Maarten, Verhaar, Marianne, Tytgat, Godelieve A.M., Kemmeren, Patrick, de Krijger, Ronald R., Al-Saadi, Reem, Pritchard-Jones, Kathy, Kool, Marcel, Rios, Anne C., van den Heuvel-Eibrink, Marry M., Molenaar, Jan J., van Boxtel, Ruben, Holstege, Frank C.P., Clevers, Hans, Drost, Jarno, Nefro Vasculaire Geneeskunde, Groep Holstege, CMM Groep Klumperman, MS Nefrologie, Regenerative Medicine and Stem Cells, Circulatory Health, Pathologie Groep Blokx, Pathologie Pathologen staf, Child Health, CMM Groep Cuppen, Cancer, CMM Sectie Molecular Cancer Research, Hubrecht Institute with UMC, Calandrini, Camilla, Schutgens, Frans, Oka, Rurika, Margaritis, Thanasis, Candelli, Tito, Mathijsen, Luka, Ammerlaan, Carola, van Ineveld, Ravian L., Derakhshan, Sepide, de Haan, Sanne, Dolman, Emmy, Lijnzaad, Philip, Custers, Lars, Begthel, Harry, Kerstens, Hindrik H.D., Visser, Lindy L., Rookmaaker, Maarten, Verhaar, Marianne, Tytgat, Godelieve A.M., Kemmeren, Patrick, de Krijger, Ronald R., Al-Saadi, Reem, Pritchard-Jones, Kathy, Kool, Marcel, Rios, Anne C., van den Heuvel-Eibrink, Marry M., Molenaar, Jan J., van Boxtel, Ruben, Holstege, Frank C.P., Clevers, Hans, and Drost, Jarno

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results